Sickle Cell Treatment Options Limited Following Drug Withdrawal
At the recent American Society of Hematology (ASH) conference, medical professionals highlighted the ongoing challenges in treating sickle cell disease. discussions centered around the limited treatment landscape, notably after the withdrawal of Pfizer’s Oxbryta (voxelotor) from the market.
“hematologists at ASH lamented the loss of Oxbryta for sickle cell patients” (Shutterstock). Clinicians weighed the pros and cons of various treatment options, considering both disease-modifying therapies and potentially curative approaches.
Limited Treatment Landscape
The lack of diverse and readily available treatments for sickle cell disease remains a important concern. Discussions at ASH underscored the urgent need for continued research and growth of new therapies to improve patient outcomes.
Alexandra Hartman Editor-in-Chief
Editor-in-Chief Prize-winning journalist with over 20 years of international news experience. Alexandra leads the editorial team, ensuring every story meets the highest standards of accuracy and journalistic integrity.
